BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32013644)

  • 21. Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome.
    Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Guo R; Tierens A; Minden MD; Chang H
    Hum Pathol; 2020 Oct; 104():117-126. PubMed ID: 32798550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
    Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
    Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?
    Tawana K; Drazer MW; Churpek JE
    Leukemia; 2018 Jul; 32(7):1482-1492. PubMed ID: 29483711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
    Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
    Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SETBP1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Yao XY; Zhou JD; Yang J; Zhang W; Ma JC; Wen XM; Yao DM; Xu ZJ; Wu DH; He PF; Qian J; Lin J
    Pathol Res Pract; 2018 May; 214(5):706-712. PubMed ID: 29549983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Yu J; Li Y; Li T; Li Y; Xing H; Sun H; Sun L; Wan D; Liu Y; Xie X; Jiang Z
    Exp Hematol Oncol; 2020; 9():2. PubMed ID: 31921515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Research progress on mechanism of MDS transformation into AML].
    Wang LL; Gao C; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition.
    Giudice V; Serio B; Errichiello S; Ferrara I; Galdiero A; Bertolini A; Visconti R; De Novellis D; Guariglia R; Luponio S; Morini D; Della Corte AM; Sessa AM; Verdesca F; Langella M; Izzo B; Selleri C
    Eur J Haematol; 2023 Nov; 111(5):729-741. PubMed ID: 37501402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
    Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
    Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
    Miesner M; Haferlach C; Bacher U; Weiss T; Macijewski K; Kohlmann A; Klein HU; Dugas M; Kern W; Schnittger S; Haferlach T
    Blood; 2010 Oct; 116(15):2742-51. PubMed ID: 20581309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.
    Weinberg OK; Siddon A; Madanat YF; Gagan J; Arber DA; Dal Cin P; Narayanan D; Ouseph MM; Kurzer JH; Hasserjian RP
    Blood Adv; 2022 May; 6(9):2847-2853. PubMed ID: 35073573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis].
    Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Zavras PD; Sinanidis I; Tsakiroglou P; Karantanos T
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts.
    Shen K; Hu DY; Zhang ZB; Guo YS; Zhang FH; Chen SN
    Int J Lab Hematol; 2023 Jun; 45(3):344-352. PubMed ID: 36860196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
    Larsson CA; Cote G; Quintás-Cardama A
    Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia.
    Bănescu C; Tripon F; Muntean C
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.
    Estey E; Hasserjian RP; Döhner H
    Blood; 2022 Jan; 139(3):323-332. PubMed ID: 34111285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
    Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
    Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.